化合物信息

ID:1098

基本信息
化学结构
MolImage
分子式
C₄₇H₅₁NO₁₄
分子量
853.90614
精确质量
853.33095532
电荷
0
InChI
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKey
RCINICONZNJXQF-MZXODVADSA-N
Canonic Smiles
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@@H]3[C@]([C@H]2[C@@H]([C@]2(C(C1=C(C)[C@@H](OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)c1ccccc1)O)C2)(C)C)O)OC(=O)c1ccccc1)(CO3)OC(=O)C
Isomeric Smiles
[C@H]1(OC(=O)c2ccccc2)[C@@H]2[C@@]3(CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@@H](C2=C([C@H](C[C@]1(O)C2(C)C)OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)c1ccccc1)O)C)OC(=O)C)C)O)OC(=O)C
计算属性
JChem
LogD (pH = 7.4)
3.54
LogD (pH = 5.5)
3.54
Log P
3.54
可自由旋转的化学键
14
质子供体
4
质子受体
10
里宾斯基五规则
false
Acid pKa
11.93
极化表面积
221.29
极化性
87.13
摩尔折射率
218.29
LOG S
-6.77
名称和标识
商标名
LipoPacOnxolAbraxanePaxceedVascular WrapTaxol ATaxolEpitaxolXoranePaxene
IUPAC标准名
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
别名
7-EpitaxolABI-0077-epi-Taxol7-epi-PaclitaxelPaclitaxel7-EpipaclitaxelTaxol®NSC 125973YewtaxanOncoGel(-)-PaclitaxelPacliexTaxolAbraxaneOnxalGenaxolGenetaxylAnzataxPaclitaxelTaxol AtaxolTAXOL(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl esterPaclitaxel5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserineTaxol Apaclitaxel
IUPAC传统名
TAX taxol paclitaxel (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
API名称
Paclitaxel
数据登录号
化合物性质
理化性质
溶解度
Insoluble
Methanol
疏水性(logP)
3
熔点
213-223°C
214-216°C
蒸汽压
< 1.12 x 10-7 Torr
外观
White Solid
Powder
药理学性质
排泄
Fecal and urinary
代谢
Hepatic (CYP2C8 and CYP3A4)
给药途径
iv
半衰期
5.8 hours
妊娠期药物分类
D (US)
生物利用度
6.5% (oral)
法定药品分级
Rx-only (US)
蛋白结合率
89 to 98%
生物活性机理
Binds to the beta subunit of tubulin
Interferes with the normal function of microtubule growth by hyper-stabilisation of their structure
安全信息
澳大利亚Hazchem
2X
美国ERG指导号
154
RTECS编号
DA8340700
联合国危险货物等级
6.1
欧盟危险性物质标志
有毒 有毒 (T)
安全公开号 
S:28-36/37/39-45-53
联合国危险货物包装类别(PG)
III
MSDS下载
欧盟危险识别号(EUHIN)
6.1B
欧盟危险货物分类
T2
危险公开号 
R:25
联合国危险货物编号
2811
保存条件
Room Temperature (15-30°C)
-20°C Freezer
产品相关信息
纯度
>98%
95+%
质检报告
应用领域
Biochemical tool extensively used to study cellular shape and function.
Use limited by low solubility and scarce availability of Taxus brevifolia bark
Antileukaemic and antineoplastic agent, esp. against melanoma and ovarian tumours
Also shown to be active against oomycete fungi
生物来源
Isol. from the stem bark of Taxus brevifolia and Taxus cuspidata (Taxaceae)
分子相关蛋白质
分子图谱
暂无数据
点击上传数据
描述信息
参考文献
PubChem文献
数据源提供
• Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. Pubmed
• Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. Pubmed
• Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. Pubmed
• Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. Pubmed
• Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. Pubmed
• ABI 007. Drugs R D. 2004;5(3):155-9. Pubmed
• Letourneau, P.C., et al.: J. Cell Biol., 98, 1355 (1984)
• Markman, M., et al.: Expert. Opin. Pharmacother., 3, 755 (1984)
• Stone, G.W., et al.:
• Danesi, R., et al.: Mol. Pharmacol., 47, 1106 (1984)
• Manfredi, J.J., et al.: Pharmacol. Ther., 25, 83 (1984)
• Kingston, D.G.I. et al., J. Nat. Prod., 1982, 45, 466-470, (2',7-di-Ac)
• Horwitz, S.B. et al., Ann. N.Y. Acad. Sci., 1986, 466, 733, (rev, pharmacol)
• Kingston, D.G.I., Pharmacol. Ther., 1991, 52, 1, (rev, pharmacol)
• Joel, S.P., Chem. Ind. (London), 1994, 172, (rev)
• Kingston, D.G.I. et al., J. Nat. Prod., 1990, 53, 1; 802, (bibl, rev)
• Williams, H.J. et al., Tetrahedron, 1993, 49, 6545, (pmr, conformn)
• Suffness, M. et al., Alkaloids (N.Y.), 1985, 25, 10, (rev, pharmacol)
• Slichenmyer, W.J. et al., Anti-Cancer Drugs, 1991, 2, 519, (rev)
• Fleming, P.E. et al., J.A.C.S., 1993, 115, 805, (biosynth)
• Young, D.H. et al., Experientia, 1992, 48, 882, (antifungal activity)
• Horwitz, S.B., Trends Pharmacol. Sci., 1992, 13, 134, (rev)
• Wall, M.E., Chron. Drug Discovery, 1993, 3, 327, (rev)
• Hoke, S.H. et al., J. Nat. Prod., 1994, 57, 277, (ms)
• Wani, M.S. et al., J.A.C.S., 1971, 93, 2325, (isol, nmr, ms, ir, uv)
• Falzone, C.J. et al., Tet. Lett., 1992, 33, 1169, (pmr, cmr)
• Ojima, I. et al., Tetrahedron, 1992, 48, 6985, (synth)
• Wheeler, N.C. et al., J. Nat. Prod., 1992, 55, 432, (occur)
• Hilton, B.D. et al., J. Nat. Prod., 1992, 55, 1157, (pmr)
• Stierle, A. et al., Science (Washington, D.C.), 1993, 260, 214, (isol, ms)
• Rose, W.C., Anti-Cancer Drugs, 1992, 3, 311, (rev)
• Winkler, J.D. et al., Tetrahedron, 1992, 48, 6953, (rev)
• Nicolaou, K.C. et al., Angew. Chem., Int. Ed., 1994, 33, 15, (rev)
• Huang, C.H.O. et al., J. Nat. Prod., 1986, 49, 665, (isol, deriv)
• Blechert, S. et al., Alkaloids (N.Y.), 1990, 39, 195, (rev, pharmacol)
• Potier, P., Chem. Soc. Rev., 1992, 21, 113, (rev)
• Chmurny, G.N. et al., J. Nat. Prod., 1992, 55, 414, (pmr, cmr)
• Zhang, H. et al., Yunnan Zhiwu Yanjiu, 1993, 15, 424; CA, 121, 78282e
• Sonnichsen, D.S. et al., Clin. Pharmacokinet., 1994, 27, 256, (rev, pharmacokinet)
• Hongjie, Z. et al., Heterocycles, 1994, 38, 975
• Gimon, M.E. et al., J. Nat. Prod., 1994, 57, 1404, (ms)
• Nicolaou, K.C. et al., Nature (London), 1994, 367, 630, (synth)
• Nicolaou, K.C. et al., J.A.C.S., 1995, 117, 624; 634; 645; 653, (synth)
• Taxol: Science and Applications, Ed., Suffness, M, CRC Press, Boca Raton, USA, 1995, (book)
• Shiina, I. et al., Chem. Lett., 1998, 3-4, (synth)
• Mukaiyama, T. et al., Chem. Eur. J., 1999, 5, 121-161, (Taxol, synth, rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 556
• Kerns, E.H. et al., J. Nat. Prod., 1994, 57, 1391, (ms)
• Fleming, P.E. et al., Pure Appl. Chem., 1994, 66, 2045, (biosynth)
• Kingston, D.G.I. et al., Tet. Lett., 1994, 35, 4483, (synth)
• Nogales, E. et al., Nature (London), 1995, 375, 424
• Danishefsky, S.J. et al., J.A.C.S., 1996, 118, 2843, (synth)
• Heinstein, P. et al., J.C.S. Perkin 1, 1996, 845, (ms)
• Gao, Q. et al., Acta Cryst. C, 1995, 51, 295, (cryst struct)
• Rowinsky, E.K. et al., N. Engl. J. Med., 1995, 332, 1004, (use, tox, rev)
• Wender, P.A. et al., J.A.C.S., 1997, 119, 2757, (synth)
• Gennari, C. et al., J.O.C., 1997, 62, 4746-4755, (synth)
• Kusama, H. et al., J.A.C.S., 2000, 122, 3811-3820, (synth)
• Huizing, M.T. et al., J. Chromatogr., B: Biomed. Appl., 1995, 664, 373, (hplc)
• Baloglu, E. et al., J. Nat. Prod., 1999, 62, 1068-1071, (synth)
• Vyas, D.M. et al., Prog. Med. Chem., 1995, 32, 289, (rev)
• Nicolaou, K.C. et al., Classics in Total Synthesis, Targets, Strategies, Methods, VCH, 1996, 655, (bibl, synth)
• Walker, K. et al., Phytochemistry, 2001, 58, 1-7, (biosynth, rev)
• The Chemistry and Pharmacology of Taxol(R) and its Derivatives, (Ed. Farina, V.), Elsevier, 1995, (book)
• Gao, Q. et al., Tetrahedron, 1996, 52, 2291, (cryst struct)
• Eisenhauer, E.A. et al., Drugs, 1998, 55, 5-30, (pharmacol, rev)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, TAH775
• Holton, R.A. et al., J.A.C.S., 1994, 116, 1597; 1599, (synth)
• Fleming, P.E. et al., J.A.C.S., 1994, 116, 4137, (biosynth)
• Georg, G.I. et al., ACS Symp. Ser., 1995, 583, (book)
• Grothaus, P.G. et al., J. Nat. Prod., 1995, 58, 1003, (immunoassay)
• Rao, K.V., J. Het. Chem., 1997, 34, 675-680, (synth)
• Hezari, M. et al., Planta Med., 1997, 63, 291-295, (biosynth, rev)
• Ranson, M. et al., Expert Opin. Invest. Drugs, 1999, 8, 837-848
• Das, B. et al., Indian J. Chem., Sect. B, 1999, 38, 1018-1024, (rev)
生物活性
PubChem BioAssay
导 航